Abstracts
METHODS:
A historical case series sample of 591 patients diagnosed between 1993 and 1999, and treated in 12 practice sites with CHOP chemotherapy was used. Baseline anemia was defined as a hemoglobin (Hb) value Ͻ12 g/dl at baseline. Multiple logistic regression was used to determine factors associated with baseline anemia and model its relationship with response [no response (NR) 
CONCLUSION:
The results support previous findings of the high prevalence of, and risk factors associated with, baseline anemia prior to CHOP chemotherapy. Baseline anemia was a significant risk factor for NR to CHOP chemotherapy, even after controlling for age, stage, and LDH. We conclude that additional studies with a comprehensive set of known risk factors validating this relationship between baseline anemia and response to CHOP chemotherapy are warranted. Centre René Huguenin, Saint Cloud, France OBJECTIVE: Breast cancer is one of the major causes of premature death for women. The management of its cost is important for both the national health insurance and the individual health-care providers. The objective of this study was to assess the global medical cost of breast cancer, from diagnosis to follow up, in a French medical centre. METHODS: Our evaluation was based on a retrospective cohort of 120 patients followed from January 1995 to February 2000 at Centre René Huguenin (SaintCloud). Comprehensive treatment schemes and clinical events were reported from patients' medical files. Detailed medical consumptions and mean duration of staff occupation were obtained primarily from direct observa-tion of the Centre's activities, for each modality of patient follow-up and treatment (surgery, radiotherapy, chemotherapy, consultations 
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COST OF TREATMENT AND FOLLOW UP OF BREAST CANCER. A RETROSPECTIVE EVALUATION IN A COMPREHENSIVE CANCER CENTRE
OBJECTIVE:
To compare the pharmacoeconomic results of a breast cancer treatment model for Japan using several criteria, including level of evidence of the clinical data.
METHODS:
The Japanese Breast Cancer Treatment Model (JBCTM) features treatment pathways for four breast cancer stages. The model includes resources, costs, and clinical outcomes for all treatments, and has the ability to estimate the cost-effectiveness of treatments in various settings with consideration given to the level of evidence. Guidelines from the American Society of Clinical Oncology (ASCO) were used to stratify the clinical data for drug treatments in the model. The ASCO levels of evidence criteria are ranked from Level I, evidence from studies showing the highest level of clinical results supporting treatment usage, to Level V, those yielding the weakest evidence for usage. For the JBCTM, the ASCO definitions of Levels I and II were directly followed and Levels III through V were combined into one level. The model contains over 450 level-of-evidence references for more than 60 drug treatments. An example of an evaluation using the JBCTM is a cost-effectiveness analysis comparing one chemotherapy combination, CAF, to two other regimens, CEF and CMF in advanced breast cancer. RESULTS: Although the incremental cost-effectiveness ratio for CAF compared to CEF is negative, indicating CAF is a dominant strategy, the clinical evidence is only Level II. In contrast, the incremental cost-effectiveness ratio for CAF compared to CMF is positive, although relatively low at 14,087¥ for each percentage increase in objective response, but the clinical evidence is Level I, the highest possible. CONCLUSIONS: Although the cost-effectiveness ratios show that CAF is more cost-effective when compared to CEF than when compared to CMF, the evidence level for choosing CAF over CMF is higher. Decision-makers can be more informed by considering both levels of evidence and pharmacoeconomic data.
